Table 2 Spearman correlation coefficients between changes in plasma lyso-Gb3 and changes in LVMi, eGFR, pain, and KIC Gb3 at specific timepoints during migalastat treatment.

From: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

  

Overall (N = 97)

ERT-naive (n = 48)

ERT-experienced (n = 49)

Males (n = 37)

Females (n = 60)

Age ≤ 40 years (n = 31)

Age > 40 years (n = 66)

Parameter

Visit

na

P valueb

na

P valueb

na

P valueb

na

P valueb

na

P valueb

na

P valueb

na

P valueb

LVMi

Month 12

55

0.9283

17

0.5164

38

0.5311

21

0.4506

34

0.2742

16

0.4782

39

0.9254

 

Month 18

44

0.5210

10

0.6515

34

0.9133

19

0.0663

25

0.4538

8

0.2604

36

0.1185

 

Month 24

13

0.8164

13

0.8164

0

NA

3

0.6667

10

0.1921

6

0.1108

7

0.2939

 

Month 30

27

0.2404

0

NA

27

0.2404

11

0.4669

16

0.1682

4

0.2000

23

0.3144

 

Month 36

3

0.6667

0

NA

3

0.6667

1

NA

2

NA

0

NA

3

0.6667

eGFR

Month 12

61

0.1294

18

0.9773

43

0.1338

23

0.6183

38

0.1072

18

0.8357

43

0.0189

 

Month 18

52

0.1052

13

0.8166

39

0.3793

21

0.0320

31

0.6475

11

0.7092

41

0.0660

 

Month 24

27

0.4925

16

0.8201

11

0.2981

8

0.2894

19

0.9943

10

0.2763

17

0.1743

 

Month 30

37

0.5586

0

NA

37

0.5586

15

0.8298

22

0.4373

6

0.8717

31

0.4231

 

Month 36

29

0.3506

0

NA

29

0.3506

11

0.7092

18

0.2795

4

0.6000

25

0.2165

Pain

Month 12

61

0.8523

18

0.6612

43

0.8123

23

0.2968

38

0.1402

18

0.9224

43

0.6802

 

Month 18

48

0.1935

13

0.3920

35

0.4525

20

0.8846

28

0.1310

10

0.1004

38

0.5628

 

Month 24

18

0.8782

16

0.7804

2

NA

6

0.3123

12

0.8353

8

0.9081

10

0.8633

 

Month 30

29

0.3309

0

NA

29

0.3309

13

0.3157

16

0.5872

4

0.4000

25

0.4522

 

Month 36

5

0.4925

0

NA

5

0.4925

2

NA

3

1.0000

1

NA

4

0.2000

KIC Gb3c

Month 6

18

0.0003

18

0.0003

NA

NA

5

0.0374

13

0.0707

10

0.0022

7

0.0208

 

Month 12

17

0.0470

17

0.0470

NA

NA

4

0.6000

13

0.7208

10

0.1076

8

0.4821

  1. eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, Gb3 globotriaosylceramide, KIC kidney interstitial capillary, LVMi left ventricular mass index, lyso-Gb3 globotriaosylsphingosine, NA not applicable.
  2. an indicates number of patients with values for both lyso-Gb3 and the other assessment at the specified timepoint.
  3. bP values represent Spearman correlations.
  4. cKIC Gb3 data were derived from FACETS only.